Altus Pharmaceuticals - Worst Pharma Stocks of 2007
Company: Altus Pharmaceuticals
Starting stock price: $19.19
Ending stock price: $5.18
Percent Change: -73.01%
Details: In July Altus lost orphan drug status for its experimental pancreatic insufficiency therapy; the FDA said the number of patients with the condition exceeds the 200,000 mark required for an orphan drug. But the real blow came in December when Genentech return the North American rights to ALTU-238, a growth hormone. Altus is looking for another partner for the drug.
More News:
Altus shares dive as Genentech hands back drug rights. Report
Altus loses orphan drug status. Report
Altus inks $140M pact for human growth hormone. Report
Altus stock plunges on clinical trial delay. Report
More stories about Altus Pharmaceuticals
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
